Alligator and Scandion claim combination success

2 September 2021
alligator-bioscience-large

Swedish biotech pairing Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) have concluded a research collaboration, describing its outcome as positive.

This collaboration was aimed at exploring the anti-tumor efficacy of Alligator’s CD40 antibody mitazalimab in chemotherapy-resistant pre-clinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with Scandion’s SCO-101.

"Opens the door for harvesting the value of this successful study with larger players"The hypothesis that was tested was to see if SCO-101, as compared to saline control, will revert chemotherapy resistance and thereby facilitate a strengthening of the anti-tumor effects of mitazalimab.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology